FCCG414QD3C50 Vidiny (USD) [237pcs Stock]
- 1 pcs$236.19158
- 2 pcs$235.01650
- Ampahany:
- FCCG414QD3C50
- Manufacturer:
- Finisar Corporation
- Famaritana antsipirihany:
- CABLE OPT 4X14G QSFP CBL ENDS EL. Fiber Optic Cable Assemblies 4x14G, full-duplex, QSFP cable ends, electrical limiting interface, RoHS, multimode, 0/70 C operation, 850nm VCSEL array, PIN array, round riser/LSZH cable, 50m length, Ge
- Manufacturer's standard lead time:
- Ao amin'ny staoky
- Fiainana an-trano:
- Iray taona
- Chip From:
- Hong Kong
- RoHS:
- Fomba fandoavam-bola:
-
- Fomba fandefasana:
- Fianakaviana:
- KEY Components Co., LTD dia Elektronika Mpanome Elektronika izay manolotra sokajy vokatra ao anatin'izany: Tariby Smart, Eo anelanelan'ny Cables Adapter, D-Shaped, tariby afovoany, Tondraka - tariby herinaratra, Tariby afon-tsolika (IEEE 1394), Jiro, tariby an-tariby ary tariby fanitarana, Cables LGH and Fivoriana tariby boribory ...
- Ny tombony azo amin'ny fifaninanana:
- We specialize in Finisar Corporation FCCG414QD3C50 electronic components. FCCG414QD3C50 can be shipped within 24 hours after order. If you have any demands for FCCG414QD3C50, Please submit a Request for Quotation here or send us an email: rfq@key-components.com
FCCG414QD3C50 Toetran'ny vokatra
Ampahany :
FCCG414QD3C50
Manufacturer :
Finisar Corporation
Description :
CABLE OPT 4X14G QSFP CBL ENDS EL
Series :
-
Ampahany :
Active
Mpamatsy tariby :
-
Isan'ny laharana :
-
Type mpamatsy :
-
Gender :
-
Karazana fifadian-kanina :
-
Toetoetra :
-
Karazana tariby :
-
Fampiasana :
-
Length :
-
Color :
-
fiarovana :
-
Vaovao farany
Mety ho liana koa ianao
-
N282-03M-28-BK
Tripp Lite
CABLE QSFP M-M 3M. Ethernet Cables / Networking Cables 3M QSFP28 to QSFP28 100Gbe Passive DAC Copper InfiniBand Cable
-
N282-02M-28-BK
Tripp Lite
CABLE QSFP M-M 2M. Ethernet Cables / Networking Cables 2M QSFP28 to QSFP28 100Gbe Passive DAC Copper InfiniBand Cable
-
-
-
-
Faritra mafana
- 6A44-B0421-027.0-0
- FCBG414QB1C07
- FCBG125SD1C10
- 0887614610
- 1003453301
- 0747521108
- 0745472061
- 6A22-D0421-021.0-0
- 1003451151
- ICD056GVP163D-70
- FCBN425QD1C03
- 1003451051
- PCIEC-036-0250-EC-EC
- 6A11-A0141-026.0-0
- 6A11-A0121-017.0-0
- ICD150GVP341A-10
- AK-ESATA-SB1-R
- 0745470003
- 6A11-A0141-020.0-0
- 10018960-N1000AULF
- 6A22-A0441-090.0-0
- 10087902-066RLF
- 1064152005
- ICD150GVP244H-10
- 0795763008
- FCBR425QD1C30
- 6A22-A0441-029.0-0
- 10126213-A02502JLF
- ICD150GVP2410-02
- 6A44-B0421-080.0-0
- 1110404505
- 1110251300
- ICD056GVP163D-15
- ICD120GVP2420-50
- 1110251209
- 6A44-B0441-080.0-0
- 10115005-7SR910HLF
- 10115005-7SR545HLF
- 10115441-15R075HLF
- 10115441-15R135HLF